| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
H1N1(IC50= 70 nM)
CBS1117 targets the hemagglutinin (HA) protein of the influenza A virus. HA is a glycoprotein on the viral surface that mediates the attachment and fusion of the virus with the host cell membrane. By interfering with the HA-mediated fusion process, CBS1117 prevents the virus from entering the host cell, thereby blocking infection. |
|---|---|
| ln Vitro |
CBS1117 exhibits an excellent antiviral selectivity index value (SI value of 3914) in the human lung epithelial cell line (A549), owing to its higher CC50 value of 274 μM and lower IC50 value of 70 nM[1].
In vitro, CBS1117 exhibits potent antiviral activity. It has an IC50 of 70 nM against the H1N1 influenza A virus (A/Puerto Rico/8/34 strain) in A549 human lung epithelial cells. It shows low cytotoxicity, with a CC50 of 274 µM, leading to an excellent antiviral selectivity index (SI) value of 3914. |
| ln Vivo |
In vivo activity of CBS1117 is not detailed in the provided search results. As a viral entry inhibitor, its potential in vivo application would be for the treatment or prevention of influenza A virus infections. Its efficacy and safety would need to be confirmed in animal models.
|
| Enzyme Assay |
Non-cellular assays for CBS1117 involve measuring its inhibition of HA-mediated membrane fusion. These assays can use recombinant HA protein and liposomes or red blood cells to model the fusion process. The compound's ability to inhibit this fusion is measured, confirming its mechanism of action.
|
| Cell Assay |
In vitro cellular assays for CBS1117 are conducted in A549 human lung epithelial cells infected with the influenza A virus. Cells are treated with the compound, and viral replication is measured by quantifying viral RNA or by plaque reduction assays. Cytotoxicity is assessed using standard cell viability assays (e.g., MTT) to determine the CC50.
|
| Animal Protocol |
Dedicated in vivo animal experiments for CBS1117 are not detailed in the provided search results. If conducted, they would likely involve mouse models of influenza A virus infection. The compound would be administered, and its effects on viral load, survival, and clinical signs of infection would be assessed.
|
| ADME/Pharmacokinetics |
CBS1117 has a molecular weight of approximately 337.3 g/mol. It is soluble in DMSO and is typically stored as a powder at -20°C. Its pharmacokinetic properties, such as oral bioavailability and half-life, would need to be characterized for in vivo use.
|
| Toxicity/Toxicokinetics |
Toxicological data for CBS1117 are limited. The compound is intended for research use only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
CBS1117 is a potent entry inhibitor of the influenza A virus (H1N1). It targets the hemagglutinin (HA) protein and interferes with HA-mediated fusion. It has an IC50 of 70 nM and a high selectivity index (SI = 3914).
|
| Molecular Formula |
C15H20CL2N2O
|
|---|---|
| Molecular Weight |
315.238101959229
|
| Exact Mass |
314.095
|
| CAS # |
959245-08-0
|
| PubChem CID |
25236799
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.8
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
20
|
| Complexity |
320
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1C(Cl)=CC=CC=1Cl)NC1CCN(C(C)C)CC1
|
| InChi Key |
OUZZSIOQTSNTTI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H20Cl2N2O/c1-10(2)19-8-6-11(7-9-19)18-15(20)14-12(16)4-3-5-13(14)17/h3-5,10-11H,6-9H2,1-2H3,(H,18,20)
|
| Chemical Name |
2,6-dichloro-N-(1-propan-2-ylpiperidin-4-yl)benzamide
|
| Synonyms |
CHEMBL4438419; SCHEMBL24665417; DTXSID101198257; CBS-1117; STK492633;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~793.05 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.60 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.60 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.60 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1722 mL | 15.8609 mL | 31.7219 mL | |
| 5 mM | 0.6344 mL | 3.1722 mL | 6.3444 mL | |
| 10 mM | 0.3172 mL | 1.5861 mL | 3.1722 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
